• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Earnings Scheduled For March 6, 2023

    3/6/23 8:52:25 AM ET
    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ADAP alert in real time by email

    Companies Reporting Before The Bell

    • Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter.

    • Precigen (NASDAQ:PGEN) is projected to report quarterly loss at $0.10 per share on revenue of $6.21 million.

    • Quanterix (NASDAQ:QTRX) is projected to report quarterly loss at $0.47 per share on revenue of $25.78 million.

    • Lordstown Motors (NASDAQ:RIDE) is estimated to report quarterly loss at $0.27 per share on revenue of $1.29 million.

    • Adaptimmune Therapeutics (NASDAQ:ADAP) is projected to report quarterly loss at $0.25 per share on revenue of $4.12 million.

    • Biodesix (NASDAQ:BDSX) is likely to report earnings for its fourth quarter.

    • Quantum-Si (NASDAQ:QSI) is projected to report earnings for its fourth quarter.

    • Science 37 Hldgs (NASDAQ:SNCE) is expected to report quarterly loss at $0.18 per share on revenue of $14.21 million.

    • GEO Group (NYSE:GEO) is likely to report quarterly earnings at $0.05 per share on revenue of $35.42 million.

    • CECO Environmental (NASDAQ:CECO) is estimated to report quarterly earnings at $0.16 per share on revenue of $105.10 million.

    • L.B. Foster (NASDAQ:FSTR) is projected to report quarterly earnings at $0.03 per share on revenue of $127.35 million.

    • Azul (NYSE:AZUL) is projected to report quarterly loss at $0.44 per share on revenue of $931.75 million.

    • Ciena (NYSE:CIEN) is expected to report quarterly earnings at $0.58 per share on revenue of $1.04 billion.

    Companies Reporting After The Bell

    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) is expected to report earnings for its fourth quarter.

    • Intrusion (NASDAQ:INTZ) is expected to report quarterly loss at $0.20 per share on revenue of $2.30 million.

    • Coherus BioSciences (NASDAQ:CHRS) is likely to report quarterly loss at $0.69 per share on revenue of $48.38 million.

    • NCS Multistage Holdings (NASDAQ:NCSM) is expected to report earnings for its fourth quarter.

    • Immuneering (NASDAQ:IMRX) is projected to report quarterly loss at $0.58 per share on revenue of $60 thousand.

    • Intrepid Potash (NYSE:IPI) is estimated to report quarterly earnings at $0.94 per share on revenue of $50.30 million.

    • CTI BioPharma (NASDAQ:CTIC) is likely to report earnings for its fourth quarter.

    • Trip.com Group (NASDAQ:TCOM) is estimated to report earnings for its fourth quarter.

    • Crawford & Company Common Stock (NYSE:CRD) is expected to report earnings for its fourth quarter.

    • Crawford & Company Common Stock (NYSE:CRD) is projected to report quarterly earnings at $0.17 per share on revenue of $300.20 million.

    • Calavo Growers (NASDAQ:CVGW) is projected to report quarterly earnings at $0.24 per share on revenue of $270.57 million.

    • RxSight (NASDAQ:RXST) is projected to report quarterly loss at $0.73 per share on revenue of $15.05 million.

    • Anika Therapeutics (NASDAQ:ANIK) is expected to report quarterly loss at $0.24 per share on revenue of $37.70 million.

    • HighPeak Energy (NASDAQ:HPK) is projected to report quarterly earnings at $0.87 per share on revenue of $253.49 million.

    • AerSale (NASDAQ:ASLE) is expected to report quarterly earnings at $0.20 per share on revenue of $122.66 million.

    • Nutanix (NASDAQ:NTNX) is projected to report quarterly earnings at $0.11 per share on revenue of $464.96 million.

    • ThredUp (NASDAQ:TDUP) is likely to report quarterly loss at $0.20 per share on revenue of $62.92 million.

    • Akoya Biosciences (NASDAQ:AKYA) is estimated to report quarterly loss at $0.43 per share on revenue of $20.58 million.

    • Dave (NASDAQ:DAVE) is projected to report quarterly loss at $1.95 per share on revenue of $59.97 million.

    • NeoGames (NASDAQ:NGMS) is estimated to report quarterly loss at $0.13 per share on revenue of $75.36 million.

    • Banco BBVA Argentina (NYSE:BBAR) is likely to report quarterly earnings at $0.32 per share on revenue of $222.99 million.

    • Markforged Holding (NYSE:MKFG) is expected to report quarterly loss at $0.07 per share on revenue of $29.35 million.

    • Ellington Residential (NYSE:EARN) is projected to report quarterly earnings at $0.22 per share on revenue of $3.92 million.

    • P10 (NYSE:PX) is expected to report quarterly earnings at $0.21 per share on revenue of $50.90 million.

    • ObsEva (NASDAQ:OBSV) is projected to report earnings for its fourth quarter.

    • Zynex (NASDAQ:ZYXI) is estimated to report quarterly earnings at $0.19 per share on revenue of $49.71 million.

    • Cara Therapeutics (NASDAQ:CARA) is estimated to report quarterly loss at $0.32 per share on revenue of $16.25 million.

    • Aris Water Solutions (NYSE:ARIS) is likely to report quarterly earnings at $0.34 per share on revenue of $128.53 million.

    • Commercial Vehicle Group (NASDAQ:CVGI) is expected to report quarterly earnings at $0.17 per share on revenue of $248.69 million.

    • Grindr (NYSE:GRND) is likely to report earnings for its fourth quarter.

    • WW International (NASDAQ:WW) is projected to report quarterly loss at $0.02 per share on revenue of $224.25 million.

    • Orthofix Medical (NASDAQ:OFIX) is estimated to report quarterly earnings at $0.34 per share on revenue of $121.84 million.

    • Guidewire Software (NYSE:GWRE) is estimated to report quarterly loss at $0.09 per share on revenue of $214.67 million.

    • Gaia (NASDAQ:GAIA) is projected to report quarterly loss at $0.02 per share on revenue of $20.00 million.

    • Pactiv Evergreen (NASDAQ:PTVE) is likely to report quarterly earnings at $0.08 per share on revenue of $1.51 billion.

    • Tabula Rasa HealthCare (NASDAQ:TRHC) is projected to report quarterly loss at $0.06 per share on revenue of $82.48 million.

    • Ocular Therapeutix (NASDAQ:OCUL) is projected to report quarterly loss at $0.25 per share on revenue of $13.53 million.

    • AeroVironment (NASDAQ:AVAV) is likely to report quarterly earnings at $1.08 per share on revenue of $169.87 million.

    • Domo (NASDAQ:DOMO) is likely to report quarterly loss at $0.12 per share on revenue of $79.47 million.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAP
    $AKYA
    $ANIK
    $ARIS

    CompanyDatePrice TargetRatingAnalyst
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    Dave Inc.
    $DAVE
    2/9/2026Outperform
    Keefe Bruyette
    RxSight Inc.
    $RXST
    1/30/2026Mkt Perform
    William Blair
    Orthofix Medical Inc.
    $OFIX
    1/27/2026$14.00Hold
    TD Cowen
    Coherus Oncology Inc.
    $CHRS
    1/23/2026$10.00Outperform
    Oppenheimer
    Ciena Corporation
    $CIEN
    1/20/2026Buy → Neutral
    BofA Securities
    Nutanix Inc.
    $NTNX
    1/15/2026$53.00Overweight → Equal Weight
    Barclays
    Nutanix Inc.
    $NTNX
    1/12/2026Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Emeritus Director Schuler Jack W bought $1,180,736 worth of shares (100,000 units at $11.81) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/27/26 9:29:02 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Emeritus Director Schuler Jack W bought $903,561 worth of shares (82,465 units at $10.96) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    1/26/26 9:28:57 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ThredUp Inc.

    SCHEDULE 13G/A - ThredUp Inc. (0001484778) (Subject)

    2/11/26 4:45:10 PM ET
    $TDUP
    Catalog/Specialty Distribution
    Consumer Discretionary

    Ellington Credit Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Ellington Credit Co (0001560672) (Filer)

    2/9/26 4:55:45 PM ET
    $EARN
    Real Estate Investment Trusts
    Real Estate

    SEC Form 6-K filed by Trip.com Group Limited

    6-K - Trip.com Group Ltd (0001269238) (Filer)

    2/9/26 4:01:46 PM ET
    $TCOM
    Real Estate

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Keefe Bruyette initiated coverage on Dave, Inc.

    Keefe Bruyette initiated coverage of Dave, Inc. with a rating of Outperform

    2/9/26 7:01:11 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    William Blair initiated coverage on RxSight

    William Blair initiated coverage of RxSight with a rating of Mkt Perform

    1/30/26 7:00:55 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we

    2/11/26 4:10:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    AV Welcomes Stephen Voline as Senior Director, Washington Operations

    Experienced defense policy and government relations leader brings decades of military, legislative, and industry expertise to AV's Washington Operations team AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced that Stephen Voline has joined the company as Senior Director of Washington Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211855975/en/Stephen Voline brings more than three decades of experience across military operations, defense policy, and industry advocacy. Voline will support AV's engagement with Congress, the Department of War, and key national security stak

    2/11/26 7:30:00 AM ET
    $AVAV
    Aerospace
    Industrials

    Domo Launches Domo MMM, an AI-Powered Marketing Measurement Service Built for Real Budget Accountability

    New AI Sidekick for marketers helps leaders identify true incremental impact, eliminate waste, and reallocate spend with confidence Domo (NASDAQ:DOMO) today announced the launch of Domo MMM, a new AI-sidekick for marketers that powers measurement and is designed to help organizations understand which marketing investments are truly driving growth and which are not. Developed in collaboration with Stella Growth Intelligence, Domo MMM brings causal marketing measurement, scenario modeling, and AI-guided recommendations directly into the flow of business decision-making. Marketing remains one of the largest and most scrutinized investments in business. Yet many organizations still rely on

    2/10/26 9:00:00 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Leadership Updates

    Live Leadership Updates

    View All

    AV Welcomes Stephen Voline as Senior Director, Washington Operations

    Experienced defense policy and government relations leader brings decades of military, legislative, and industry expertise to AV's Washington Operations team AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced that Stephen Voline has joined the company as Senior Director of Washington Operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211855975/en/Stephen Voline brings more than three decades of experience across military operations, defense policy, and industry advocacy. Voline will support AV's engagement with Congress, the Department of War, and key national security stak

    2/11/26 7:30:00 AM ET
    $AVAV
    Aerospace
    Industrials

    Fox Factory Announces Strategic Board Refresh

    Company to Appoint Two New Independent Directors and Form Transformation Committee Focused on Operational Excellence and Margin Improvement Company Enters into Cooperation Agreement with Engine Capital DULUTH, Ga., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Fox Factory Holding Corp. (Nasdaq: FOXF) ("Fox Factory" or the "Company"), a premium brand and a global leader in the design, engineering and manufacturing of performance-defining products and systems for customers worldwide, today announced that following constructive discussions with Engine Capital ("Engine Capital") regarding opportunities to enhance operational performance and profitability, the Company will be undertaking a strategic boar

    2/9/26 4:05:00 PM ET
    $FOXF
    $OFIX
    Motor Vehicles
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    CVG Announces Appointment of Ari Levy to Board of Directors

    NEW ALBANY, Ohio, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Commercial Vehicle Group (the "Company" or "CVG") (NASDAQ:CVGI), a diversified industrial products and services company, today announced that its Board of Directors ("Board") appointed Ari Levy of Lakeview Investment Group ("Lakeview") as an independent director. Lakeview owns approximately 8.9% of the outstanding shares of the Company. In connection with Mr. Levy's appointment, the Board was expanded to 7 members. Mr. Levy will serve on the Board's Nominating, Governance and Sustainability, and Audit Committees. Mr. Levy is the founder, President, and Chief Investment Officer of Lakeview Investment Group, a Chicago based Investment Mana

    2/6/26 4:05:00 PM ET
    $CVGI
    Auto Parts:O.E.M.
    Consumer Discretionary

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Development Officer Pestano Gary Anthony converted options into 1,481 shares and sold $5,445 worth of shares (540 units at $10.08), increasing direct ownership by 11% to 9,387 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:20 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Commercial Officer O'Kane Kieran converted options into 1,600 shares and sold $5,889 worth of shares (584 units at $10.08), increasing direct ownership by 13% to 8,885 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    CFO, Sec'y & Treasurer Cowie Robin Harper sold $9,489 worth of shares (941 units at $10.08) and converted options into 2,584 shares, increasing direct ownership by 12% to 15,297 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    2/11/26 6:03:21 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Financials

    Live finance-specific insights

    View All

    RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we

    2/11/26 4:10:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Quantum-Si to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will report financial results for the fourth quarter and full year 2025 on Tuesday, March 3, 2026. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternat

    2/10/26 8:00:00 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials

    Ellington Credit Declares Monthly Common Dividend

    Ellington Credit Company (NYSE:EARN) ("we" or the "Fund") today announced that its Board of Trustees has declared a monthly common dividend of $0.08 per share, payable on March 31, 2026 to common shareholders of record as of February 27, 2026. Cautionary Statement Regarding Forward-Looking Statements This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical in nature and can be identified by words such as "anticipate," "estimate," "will," "should," "may," "expect," "project," "believe," "intend," "seek," "plan" and similar expressions or their ne

    2/9/26 4:19:00 PM ET
    $EARN
    Real Estate Investment Trusts
    Real Estate

    $ADAP
    $AKYA
    $ANIK
    $ARIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by P10 Inc.

    SC 13D/A - P10, Inc. (0001841968) (Subject)

    12/13/24 9:00:20 PM ET
    $PX
    Investment Managers
    Finance

    Amendment: SEC Form SC 13D/A filed by Grindr Inc.

    SC 13D/A - Grindr Inc. (0001820144) (Subject)

    12/9/24 5:32:00 PM ET
    $GRND
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13D/A filed by Pactiv Evergreen Inc.

    SC 13D/A - Pactiv Evergreen Inc. (0001527508) (Subject)

    12/9/24 10:47:22 AM ET
    $PTVE
    Containers/Packaging
    Consumer Discretionary